Acutaas Chemicals (ACUTAAS) Q1 26/27 earnings summary

Executive summary

• Q1 FY27 began amid geopolitical tensions, but raw material supply and operations remained stable.

• Revenue from operations for Q1 FY27 grew 59.1% year-over-year to ₹3,297 million, reflecting strong business momentum and operational agility.

• Commercial supply from the new battery chemicals plant commenced after successful trials.

• Semiconductor chemicals segment benefits from structural AI-driven demand for CPUs and memory chips.

• Certified as a Great Place to Work and received Responsible Care Certification.

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were approved by the Board and reviewed by statutory auditors with no modifications.

Financial highlights

• Revenue from operations reached INR 329.7 crore (₹3,297 million), up 59.1% YoY.

• Gross profit was INR 190.9 crore (₹1,909 million), up 73% YoY; gross margin expanded to 57.9%.

• EBITDA stood at INR 113.1 crore (₹1,131 million), more than doubling YoY; EBITDA margin rose to 34.3%.

• PAT was INR 74.9 crore (₹750 million), up 70.4% YoY; PAT margin expanded to 22.7%.

• Net cash and equivalents at INR 314 crore as of June 30, 2026.

• Consolidated net profit for Q1 FY27 was ₹7,426.01 lakhs, compared to ₹4,429.34 lakhs in Q1 FY26.

• Basic EPS (consolidated) for Q1 FY27 was ₹9.07, up from ₹5.41 in Q1 FY26.

Outlook and guidance

• Confident of delivering 25% revenue growth for FY 2027 with stable margins.

• EBITDA margin expected to remain similar to FY 2026 levels.

• Specialty chemical revenue expected to grow as new products ramp up, offsetting commodity phase-out.

• CDMO business targeted to reach INR 1,000 crore revenue, with a robust product pipeline.

• Management does not expect any material impact from recent regulatory inspections on the company’s financial position, operations, or cash flows.